Virtual-reality based physiotherapy during inpatient treatment with high-dose chemotherapy for acute leucemia or autologous or allogeneic stem cell transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00031095

Enrollment

Registered

2023-06-15

Start date

2023-01-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AML, ALL in induction, autologous and allogeneic HSCT

Interventions

Group 1: VR-Intervention Group 2: Standard of care

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Written informed consent • Ability to follow instructions in German or English • Inpatient treatment for one of the following therapies: • High-dose chemotherapy for acute leukaemia • Autologous or allogeneic stem cell transplantation

Exclusion criteria

Exclusion criteria: • Serious cardiac diseases (e.g. heart failure NYHA III, myocardial infarction III • Severe pulmonary global insufficiency

Design outcomes

Primary

Measure	Time frame
Feasibility, valuation takes place at the end of the study via interviews	—

Secondary

Measure	Time frame
Strength, mobility, cognitive outcome, anxiety, depression, QoL; with evaluation over time of therapy well as at the end of treatment	—

Countries

Germany

Contacts

Public ContactFriederike Wortmann

UKSH Campus Lübeck

friederike.wortmann@uksh.de+4945150044150

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026